Article
Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices.
Diabetologia - 1 May 1995
Jeandidier N, Boivin S, Sapin R, Rosart-Ortega F, Uring-Lambert B, Réville P, Pinget M
Abstract excerpt
Intraperitoneal insulin infusion using implantable devices in insulin-dependent diabetic (IDDM) patients is promising since it improves diabetic control and decreases frequency of hypoglycaemia. However, preliminary data show a striking increase in plasma levels of anti-insulin antibodies with this therapy. In order to more precisely evaluate the immunogenicity and its consequences, anti-insulin antibody levels...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.